If you're having trouble pronouncing the name of the newly funded SGLT2 inhibitor for type 2 diabetes, you're not the only one! Watch our video guide to learn how to pronounce empagliflozin. 

EPiC, a free dashboard built for GPs interested in improving their practice with respect to equitable prescribing of funded medicines, is now available

To sign up to EPiC, simply click here to begin the two-step sign up process. 

Inequities exist in all aspects of diabetes care. In this article, Alesha Smith outlines some examples, proposes some actions, and explains where the new medicines fit in. 

This activity has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 0.5 CME credits for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes.

Late last year, PHARMAC announced the SGLT2 inhibitor empagliflozin (Jardiance®) and empagliflozin with metformin (Jardiamet®) will be funded for the treatment of type 2 diabetes under Special Authority.

Find out all you need to know about the Special Authority criteria. 

If you are a GP practising in New Zealand and would like to use a data analytics tool that can help you assess your prescribing with respect to type-2 diabetes, and allow you to compare your prescribing behaviour to your peers, then sign up now. To sign up to EPiC, simply click here to begin the two-step sign up process. 

In this webinar, Dr Rinki Murphy discusses the issue of inequity in diabetes care. You can watch this webinar here or in ELearning.